The Psychedelic Therapies Executive Order

This Viewpoint discusses the executive order supporting the development and approval of psychedelic drugs and outlines issues surrounding their ethical and evidence-based integration into clinical care.

Corresponding Author: I. Glenn Cohen, JD, Harvard Law School, Griswold Hall 503, 1525 Massachusetts Ave, Cambridge, MA 02138 (igcohen@law.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.